Publications by authors named "Shahbaz Memon"
Article Synopsis
- Nodal marginal zone lymphoma (NMZL) is a rare subtype of non-Hodgkin lymphoma, making up about 2% of cases in both children and adults, often considered to be a mild disease but can be aggressive in adults.
- A 31-month-old boy with refractory EBV-positive NMZL experienced extensive disease that did not respond to initial chemotherapy or Rituximab, prompting treatment with second-line chemotherapy and an allogeneic hematopoietic stem cell transplant (HSCT).
- This case is significant as it is the first reported instance of a pediatric patient with refractory NMZL successfully treated with allogeneic stem cell transplant, indicating potential new treatment options for similar cases.
Background: Extended family donor search other than siblings may yield an HLA matched donor in communities with high rate of consanguinity. The outcome of patients who are transplanted from non-sibling matched related donors (NS-MRD) including engraftment and graft versus host disease (GVHD) are scarce in comparison with matched sibling donor (MSD).
Methods: We retrospectively reviewed the outcome of all our pediatric hematopoietic stem cell transplantation (HSCT) patients who had non-sibling matched related donor and controlled them with matched sibling donor HSCT (based on age, indication of HSCT, conditioning regimen, GVHD prophylaxis, serotherapy, stem cell source and cytomegalovirus status).
When human leucocyte antigen-matched related donors are available, haematopoietic stem cell transplantation (HSCT) in children with severe aplastic anaemia (SAA) represents the standard of care. Cyclophosphamide (Cy) 200 mg/kg and anti-thymocyte globulin (ATG) are frequently administered, but to-date, no standard conditioning regimen exists. In this study, we investigated the efficacy of a unified HSCT conditioning protocol consisting of low-dose Cy 80 mg/kg, fludarabine and ATG.
View Article and Find Full Text PDFIntroduction: incidental prostate cancer findings reflect the great burden of prostatic cancer across the globe. Our 10 year retrospective analysis aimed to identify the incidence and clinic-pathologic features of prostate cancer incidentally detected in patients undergoing transurethral resection of the prostate (TURP) for benign prostatic hyperplasia (BPH), and to estimate the clinical value of pathologic review of all TURP specimens.
Methods: after excluding patients with a known diagnosis of prostate cancer prior to TURP a total of 2,386 men (ages 25-98) were identified by pathology (TURP) specimens.